$$$$$$$~BIG OTC DD PICKS AND LOW FLOAT MOVERS$$$$$$$

[remind2]

GOVX @ .06: MVA-VLP Vector Platform.

GOVX has made multiple deals recently with other big name research groups that want to incorporate the MVA-VLP Vector Platform into their programs.

It appears to be an ideal venue for virtually any vaccine candidate drug.

IMO, GOVX is a prime buyout candidate for may reasons, but the Platform itself is a big drawer in its own right.

Here is a snippit from todays news concerning this issue.

1-17-17:
"Therapeutic vaccine candidates will be based upon GeoVax's novel MVA-VLP vector platform, which has been proven safe in multiple human clinical trials of company's preventive HIV vaccine. This platform is also being used by GeoVax to develop preventive vaccines against Zika virus and hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa). GeoVax also recently initiated a collaborative project with The Burnet Institute to use its MVA-VLP platform to develop a vaccine to prevent malaria infection.

Link:
https://finance.yahoo.com/news/geovax-collaborate-georgia-state-university-140000368.html